Trial Profile

A phase I study of Ivermectin (mdc-STM) for treatment of Malaria

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Nov 2026 According to a MedinCell media release, funding from the Gates Foundation, including a grant of up to 3 millions dollars to advance the MDC-STM malaria program, enables company advance ivermectin SC formulation toward first-in-human trial.
03 Sep 2024 According to a MedinCell media release, the company plans to initiate the trial in 2025
26 Jun 2023 According to a MedinCell media release, the company expect to initiate this trial in 2024 with the support of Unitaid.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com